33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors
    Meeting Abstract

    Balar, A. V.; McGregor, B. A.; Rosenberg, J. E.; van der Heijden, M. S.; Park, S. H.; Lee, J. L.; Harrison, M. R.; Heath, E. I.; Stein, M. N.; Loriot, Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)
    Meeting Abstract

    Bajorin, D. F.; Witjes, J. A.; Gschwend, J.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S.; Park, S. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A
    Meeting Abstract

    Balar, A. V.; Kamat, A. M.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Grivas, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors
    Meeting Abstract

    Abida, W.; Sanay, E.; Lukashchuk, N.; Pierce, A.; de Graaf, W.; Lau, A.; Ros, V. R.; Kurian, N.; Parr, G.; LoembE, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Differential levels of serum PSA related to volume of benign, Gleason pattern 3 and pattern 4 prostate tissue
    Meeting Abstract

    Andolfi, C.; Vickers, A.; Cooperberg, M. R.; Carroll, P.; Cowan, J. E.; Paner, G. P.; Eggener, S. E.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA plus ) metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Patnaik, A.; Campbell, D.; Shapiro, J. D.; Bryce, A. H.; McDermott, R. S.; Sautois, B.; Vogelzang, N. J.; Bambury, R. M.; Voog, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib
    Meeting Abstract

    Valle, J. W.; Bibeau, K.; Cho, Y.; Ren, H.; Feliz, L.; Lihou, C. F.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation
    Meeting Abstract

    Zhu, A. X.; Macarulla, T.; Javle, M. M.; Kelley, R. K.; Lubner, S. J.; Adeva, J.; Cleary, J. M.; Catenacci, D. V. T.; Borad, M. J.; Bridgewater, J. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Population-based, real-world prognostic factors related to survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Yu, K. H.; Cockrum, P.; Surinach, A.; Wang, S.; Chu, B. C.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival
    Meeting Abstract

    Vos, E. L.; Maron, S. B.; Krell, R. W.; Nakauchi, M.; Fiasconaro, M.; Walch, H. S.; Capanu, M.; Ku, G. Y.; Ilson, D. H.; Janjigian, Y. Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save